- Home
- DHF vs SWKH Comparison
DHF vs SWKH Comparison
Compare DHF & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- SWKH
- Stock Information
- Founded
- DHF 1998
- SWKH 1996
- Country
- DHF United States
- SWKH United States
- Employees
- DHF N/A
- SWKH N/A
- Industry
- DHF Finance Companies
- SWKH Diversified Financial Services
- Sector
- DHF Finance
- SWKH Finance
- Exchange
- DHF Nasdaq
- SWKH Nasdaq
- Market Cap
- DHF 189.1M
- SWKH 176.0M
- IPO Year
- DHF N/A
- SWKH 1999
- Fundamental
- Price
- DHF $2.57
- SWKH $14.44
- Analyst Decision
- DHF
- SWKH Strong Buy
- Analyst Count
- DHF 0
- SWKH 1
- Target Price
- DHF N/A
- SWKH $18.00
- AVG Volume (30 Days)
- DHF 451.1K
- SWKH 6.8K
- Earning Date
- DHF 01-01-0001
- SWKH 11-13-2025
- Dividend Yield
- DHF 7.65%
- SWKH N/A
- EPS Growth
- DHF N/A
- SWKH 55.18
- EPS
- DHF N/A
- SWKH 1.41
- Revenue
- DHF N/A
- SWKH $37,409,000.00
- Revenue This Year
- DHF N/A
- SWKH $52.93
- Revenue Next Year
- DHF N/A
- SWKH N/A
- P/E Ratio
- DHF N/A
- SWKH $10.26
- Revenue Growth
- DHF N/A
- SWKH 47.31
- 52 Week Low
- DHF $2.06
- SWKH $12.00
- 52 Week High
- DHF $2.39
- SWKH $16.24
- Technical
- Relative Strength Index (RSI)
- DHF 41.49
- SWKH 44.93
- Support Level
- DHF $2.57
- SWKH $14.36
- Resistance Level
- DHF $2.62
- SWKH $15.15
- Average True Range (ATR)
- DHF 0.02
- SWKH 0.25
- MACD
- DHF -0.01
- SWKH 0.01
- Stochastic Oscillator
- DHF 0.00
- SWKH 11.25
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.